<DOC>
	<DOCNO>NCT00472927</DOCNO>
	<brief_summary>To evaluate three new investigational tablet formulation Food Drug Administration ( FDA ) approve medication Prempro™ , Premarin combine medroxyprogesterone acetate ( MPA ) .</brief_summary>
	<brief_title>Bioequivalence Study 3 New Formulations Premarin/MPA Compared With Premarin/MPA ( Prempro )</brief_title>
	<detailed_description />
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<criteria>Healthy , postmenopausal woman , age 35 70 year Spontaneous amenorrhea least 12 month ( FSH require ) spontaneous amenorrhea least 6 month ( FSH level ≥38 mIU/mL ) ; spontaneous amenorrhea must begin age 55 BMI range 18 35 kg/m2 History presence hypertension ( &gt; 139 mm Hg systolic &gt; 89 mm Hg diastolic ) History drug allergy conjugate estrogen ( CE ) selective estrogen receptor modulators ( SERMs ) Use prescription investigatioanl drug within 30 day test article administration</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>